Genetic Analysis AS (Spotlight Stock Market: GEAN), a Norwegian microbiome diagnostics company, on Wednesday introduced the GA-map MHI GutHealth reagent kit for Research Use Only.

The test enables advanced measurement of antibiotic-induced microbiome imbalances and has been validated for recurrent Clostridioides difficile infection (rCDI).

GA-map was co-developed by Genetic Analysis and Switzerland-based Ferring Pharmaceuticals, combining Genetic Analysis AS's PCR-based GA-map platform with Ferring's biomarker for monitoring post-antibiotic microbiome imbalances.

Initially, GA-map MHI GutHealth will focus on rCDI patients, providing clinicians with rapid insights into microbiome status and treatment response. It also offers potential as a pharmacodynamic measure in clinical trials for Live Biotherapeutic Products, Faecal Microbiota Transplants, and other microbiome restoration strategies.

With an estimated 500,000 annual CDI cases in the United States, Genetic Analysis AS positions the new test to meet significant market potential. The company expects the launch to expand its diagnostic portfolio and support future revenue growth.

GA-map is now available to laboratories using Luminex xMAP technology worldwide.